Apellis CMO Federico Grossi departs; Caroline Baumal named new CMO effective Jan 3, 2023

Apellis Pharmaceuticals, Inc.

Federico Grossi, M.D., Ph.D., leaves as Chief Medical Officer effective Jan 3, 2023 to pursue new career opportunities.
Caroline Baumal, M.D., appointed CMO effective Jan 3, 2023, succeeding Dr. Grossi.
Dr. Grossi will continue at Apellis through Feb 28, 2023 to assist transition and pegcetacoplan launch preparations.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Federico Grossi

Chief Medical Officer

APLS · Apellis Pharmaceuticals, Inc.

Effective: 2023-01-03
Successor: Caroline Baumal
Filed: January 5, 2023, 6:59 PM ET

Federico Grossi, M.D., Ph.D., the Chief Medical Officer of the Company, will be leaving the Company to pursue new career opportunities.

Appointed

Caroline Baumal

Chief Medical Officer

APLS · Apellis Pharmaceuticals, Inc.

Effective: 2023-01-03
Filed: January 5, 2023, 6:59 PM ET

Caroline Baumal, M.D. will join the Company as Chief Medical Officer, effective as of January 3, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Federico Grossi departed as Chief Medical Officer at Apellis Pharmaceuticals, Inc..

Action: leaving
Role: Chief Medical Officer

Exact text from the filing

Federico Grossi, M.D., Ph.D., the Chief Medical Officer of the Company, will be leaving the Company to pursue new career opportunities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Caroline Baumal was appointed as Chief Medical Officer at Apellis Pharmaceuticals, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Caroline Baumal, M.D. will join the Company as Chief Medical Officer, effective as of January 3, 2023.

View on SEC.gov

Apellis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-001962

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.